MedPath

STRENGTHS: Fostering responsive mental health systems in the Syrian refugee crisis

Not Applicable
Completed
Conditions
Anxiety
Mental and Behavioural Disorders
Common mental disorders
Depression
Posttraumatic stress disorder
Registration Number
ISRCTN11862037
Lead Sponsor
VU Amsterdam
Brief Summary

2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/32082506/ (added 22/08/2022)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
206
Inclusion Criteria

1. Adults of 18 years or above
2. Syrian refugee
3. Arabic-speaking
4. Elevated levels of psychological distress (K10 >15) and reduced psychosocial functioning (WHODAS 2.0 >16)

Exclusion Criteria

1. Acute medical conditions
2. Imminent suicide risk or expressed acute needs/protection risks (e.g., a young woman who expresses that she is at acute risk of being assaulted or killed)
3. Severe mental disorder (psychotic disorders, substance-dependence)
4. Severe cognitive impairment (e.g., severe intellectual disability or dementia)
5. Currently enrolled in a specialized psychological treatment program (e.g., EMDR, CBT)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Psychological distress (Hopkins Symptom Checklist; HSCL-25) at screening/baseline, 1-week post-assessment, 3-month follow-up, 12-month follow-up
Secondary Outcome Measures
NameTimeMethod
<br> Measured at screening/baseline, 1-week post-assessment, 3-month follow-up, 12-month follow-up unless noted:<br> 1. Depression (HSCL-25 subscale)<br> 2. Anxiety (HSCL-25 subscale)<br> 3. Symptoms of post traumatic stress disorder (PTSD Checklist DSM-5; PCL-5)<br> 4. Functional impairment (WHO Disability Assessment Schedule; WHODAS 2.0)<br> 5. Self-identified problems (Psychological Outcomes Profiles; PSYCHLOPS)<br> 6. Cost of care (Client Service Receipt Inventory; adapted CSRI)<br> 7. Anger (Trait Anger Scale; STAS) at baseline and 1-week post assessment<br> 8. Cortisol (hair cortisol concentrations) at baseline and 3-month follow up<br>
© Copyright 2025. All Rights Reserved by MedPath